Kapitel 76: Maligne Lymphome

Abbondanzo SL, Wenig BM (1995) Non-Hodgkin’s lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 75: 1281–1291

Abou-Elella AA, Weisenburger DD, Vose JM et al. (1999) Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 17: 784–790

Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859–863 Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:

3144–3150 Advani R, Rosenberg SA, Horning SJ. (2004) Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of

no initial therapy. J Clin Oncol 22(8):1454‒1459 Aisenberg AC (1991) Malignant lymphoma: biology, natural history, and treatment, 1st edn. Lea & Febiger,

Philadelphia London Aisenberg AC (1999) Primary large cell lymphoma of the mediastinum. Semin Oncol 26: 251–258 Alas S, Bonavida B (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in

B-Non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137–5144

Alavanja MCR, Blair A, Masters MN (1990) Cancer mortality in the U. S. flour industry. JNCI 82: 840–848 Alizadeh AA, Eisen MB, Davis REAlpen B et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by

gene expression profiling. Nature 403: 503–511 Alpen B, Kuse R, Parwaresch R et al. Ongoing monoclonal B-cell proliferation is not common in gastric B-cell

lymphoma after combined radiochemotherapy. J Clin Oncol 2004;22(15):3039-45 Alpen B, Neubauer A, Dierlamm J et al. (2000) Translocation t (11;18) absent in early gastric marginal zone B-cell

lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 95: (12):4014–4015-5 Alt FW, Oltz EM, Young F et al. (1992) VDJ recombination. Immunol Today 13: 306–314 Altekruse SF, Henley SJ, Thun MJ (1999) Deaths from hematopoietic and other cancers in relation to permanent hair

dye use in a large prospective study (United States). Cancer Causes Control 10: 617–625 American Cancer Society. Cancer facts figures 2009-2010. http://www.cancer.org/ downloads Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin’s lymphomas: distributions of

the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 9: 717–720

Ansell SM, Habermann TM, Kurtin PJ et al. (1997) Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15: 2296–2301

Arcaini L, Montanari F, Alessandrino EP et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008;19(7):1331-5

Arcaini L, Orlandi E, Scotti M et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4(4):250-2

Arcaini L, Paulli M, Boveri E et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100(1):107-15

Armitage JO (1993) Treatment of non-Hodgkin’s lymphomas. N Engl J Med 328: 1023–1030 Armitage JO, Fyfe MA, Lewis J (1984) Long-term remission durability and functional status of patients treated for

diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 2: 898–902 Armitage JO, Greer JP, Levine AM et al. (1989) Peripheral T-cell lymphoma. Cancer 63: 158–163 Armitage JO, Vose JM, Bierman PJ, Bishop MR (1994) Salvage therapy for patients with lymphoma. Sem Oncol 21:

82–85 Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of

the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16: 2780–2795 Arranz R, Garcia-Alfonso P, Sobrino P et al. (1998) Role of interferon alfa-2b in the induction and maintenance

treatment of low-grade non-Hodgkin’s lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 16: 1538–1546

Askling J, Ekbom A (2001) Risk of non-Hodgkin’s lymphoma following tuberculosis. Br J Cancer 84: 113–115 Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz MJ (1994) Adjuvant radiotherapy to sites of previous bulky disease

in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30: 799–803 Baar J, Burkes RL, Gospodarowicz M (1999) Primary non-Hodgkin’s lymphoma of bone. Semin Oncol 26: 270–275

Bagley CM Jr, DeVita VT Jr, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76: 227–234

Bahler D W, Miklos JA, Swerdlow SH (1997) Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 89: 3335–3344

Baldini L, Blini M, Guffanti A et al. (1998) Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Ann Oncol 9: 779–781

Bangerter M, Kocher F, Binder T et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974‒977

Baris D, Zahm SH (2000) Epidemiology of lymphomas. Curr Opin Oncol 12: 383–394 Barth TF, Leithauser F, Moller P (2001) Mediastinal B-cell lymphoma, a lymphoma type with several characteristics

unique among diffuse large B-cell lymphomas. Ann Hematol 80 [Suppl 3]: B49–B53 Barth TFE, Barth CA, Kestler HA, Michl P, Weniger MA, Buchholz M, Möller P, Gress T (2007) Transcriptional

profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal tract (GI) are blastic variants of GI marginal zone lymphoma. J Pathol 211: 305-313

Bastion Y, Blay JY, Divine M et al. (1997) Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol 15: 2945–2953

Bastion Y, Brice P, Haioun C et al. (1995) Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86: 3257–3262

Bayerdörffer E, Neubauer A, Rudolph B et al. (1995) Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of helicobacter pylori infection. MALT Lymphoma Study Group. Lancet ;345: 1591–-1594

Becker WS, Behr TM, Cumme F et al. (1995) 67 Ga citrate versus 99 mTc-labeled LL2-FAB (anti CD22) fragments in the staging of B-cell Non-Hodgkin’s lymphomas. Canc Res 55: 5777s–5777x

Behr TM, Griesinger F, Riggert J et al. (2002) High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 94: 1363–1372

Behr TM, Wormann B, Gramatzki M et al. (1999) Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 5: 3304s–3314s

Bell DA, Liu Y, Cortopassi GA (1995) Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst 87: 223–224

Bendandi M, Gocke CD, Kobrin CB et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5: (10):1171–1177-7

Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. (1998) ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91: 2076–2084

Benkerrou M, Jais JP, Leblond V et al. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 92: 3137–3147

Bennett JM, Catovsky D, Daniel MT et al. (1989)Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 42: 567–584

Bentink S, Wessendorf S, Schwaenen C, et al. (2008) Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia 22: 1746‒1754

Bentz M, Barth TF, Bruderlein S et al. (2001) Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 30: 393–401

Bentz M, Döhner H, Werner CA et al. (1995) Identification of genetic imbalances in malignant lymphoma using comparative genomic hybridization. Stem Cells 13: 83–87

Bentz M, Trümper L (2001) Workshop report: Genetics and immunology of aggressive NHL. Ann Hematol 80 [Suppl 3]: B5–7

Berger F, Felman P, Thieblemont C et al. (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95(6): 1950‒1956

Bertoni F, Conconi A, Capella C et al. (2002) Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 99(7): 2541‒2544

Betticher DC, Gmartinelli G, Radford JA et al. (2006) Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) Annals Oncol 17: 1546-1552

Bierman PJ, Vose JM, Anderson JR et al. (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 15: 445–450

Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235–248 Blystad AK, Enblad G, Kvaloy S H et al. (2001) High-dose therapy with autologous stem cell transplantation in

patients with peripheral T cell lymphomas. Bone Marrow Transplant 27: 711–716 Boehme V, Zeynalova S, Kloess M et al. (2007) Incidence and risk factors of central nervous system recurrence in

aggressive lymphoma – a survey of 1693 patients treated in protocols of The German High-Grade Lymphoma Study Group (DSHNHL) Annals Oncol 18:149-157

Bordeleau L, Berinstein N. (2000) Moleculalr diagnostics in follicular non-Hodgkin´s lymphoma: A review. Sem Oncol 27, Suppl 12: 42‒52

Brennan JA, Mao L, Hruban RH et al. (1995) Molecular assessment of histopathological staging in sqamous-cell carcinoma of the head and neck. N Engl J Med 332: 429–435

Brepoels L, Stroobants S, de Wever W et al. (2008) Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 49: 1693‒1701

Briggs JH, Algan O, Miller TP, Oleson JR (2002) External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin’s lymphoma. Am J Clin Oncol 25: 34–37

Brittinger G, Bartels H, Common H et al. (1986) Klinische und prognostische Relevanz der Kiel-Klassifikation der Non-Hodgkin-Lymphome. Onkologie 9: 118–125

Brown LM, Blair A, Gibson R et al. (1990) Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. Cancer Res 50: 6585–6591

Buchmann I, Reske SN (2001) Novel imaging techniques in NHL: clinical results with PET imaging. Ann Hematol 80 [Suppl 3]: B54–57

Buckley JD, Meadows AT, Kadin ME et al. (2000) Pesticide exposures in children with non-Hodgkin lymphoma. Cancer 89: 2315–2321

Bullrich F, Morris SW, Hummel M et al. (1994) Nucleophosmin (NPM) gene rearrangements in Ki-1 positive lymphomas. Canc Res 54: 2873–2877

Burkitt DP (1969) Etiology of Burkitt’s lymphoma – an alternative hypothesis to a vectored virus. J Natl Cancer Inst 42: 19–28

Burton C, Linch D, Hoskin P et al. (2006) A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin’s lymphoma. Br J Cancer 94:806-13

Buske C, Hoster E, Dreyling M et al. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5): 1504‒1508

Cairoli R, Grillo G, Tedeschi A et al. (2002) Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant 29: 473–477

Canellos GP, Skarin AT, Klatt MM et al. (1987) The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol 24, 2 (Suppl 1): 2‒7

Carella AM, Cavaliere M, Lerma E et al. (2000) Autografting followed by non-myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’sHodgkin's disease and non-Hodgkin’sHodgkin's lymphoma. J Clin Oncol 18(23): 3918–3924

Carli PM, Boutron MC, Maynadie M et al. (1994) Increase in the incidence of non-Hodgkin’s lymphomas: evidence for a recent sharp increase in France independent of AIDS. Br J Cancer 70: 713–715

Cartwright R, Brincker H, Carli PM et al. (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35: 627–633

Cerroni L, Zochling N, Putz B, Kerl H. (1997) Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol;24(8):457‒461

Chacon JI, Mollejo M, Munoz E et al. (2002) Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 100(5):1648‒1654

Chen CJ, Skingley P, Meyer RM (2000) A comparison of outcomes of elderly patients with aggressive histology lymphoma (AHL) who were entered or not entered on to a randomized phase II trial. Leukemia Lymphoma 38: 327–334

Chen LT, Lin JT, Shyu RY et al. (2001) Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 19(22): 4245‒4251

Chen LT, Lin JT, Tai JJ et al. (2005) Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst;97(18):1345‒1353

Cheng TY, Lin JT, Chen LT et al. (2006) Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 24(21): 3483‒3489

Cheson B, Horning SJ, Coiffier B et al. (1999) Report of an international workshop to standardize response criteria for Non-Hodgkin’s lymphoma. NCI Sponsored International Working Group. J Clin Oncol 17: 1244–1253

Cheson BD, Pfistner B, Juweid M et al. (2007) Revised Response Criteria for malignant lymphoma. J Clin Oncol 25: 579‒586

Cheung MM, Chan JK, Lau WH et al. (1998) Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16: 70–77

Chisesi T, Congiu M, Contu A et al. (1991) Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in lowgrade non-Hodgkin’s lymphoma: an interim report of a randomized study. Non-Hodgkin’s Lymphoma Cooperative Study Group. Eur J Cancer 27 [Suppl 4]: S31–S33

Chittal SM, Delsol G (1997) The interface of Hodgkin’s disease and anaplastic large cell lymphoma. Cancer Surv 30: 87–105

Chiu BC, Dave BJ, Blair A et al. (2006). Agricultural pesticied use and risk of t(14 ;18)-defined subtypes of non-Hdogkin lymphoma Blood 208: 1363‒1369

Clarke AR, Purdie CA, Harrison DJ et al. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849–852

Cogliatti-SB, Nowak-U, Henz S et al. (2006) Diagnosis of Burkitt lymphoma in due time: a practical approach. Br J Haematol 134: 294‒301

Coiffier B (1995) Fourteen years of high-dose CHOP (ACVB regimen): Preliminary conclusions about the treatment of aggressive-lymphoma patient s. Ann Oncol 6: 211–217

Coiffier B, Haioun C, Ketterer N et al. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927–1932

Coiffier B, Lepage E, Briere J et al. (2002) CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242

Cole MD (1986) The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 20: 361–384 Cole MD (1991) Myc meets its Max. Cell 65: 715–716 Colombat P, Salles G, Brousse N et al. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy

for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (1):101–106

Connors JM, Klimo P, Fairey RN, Voss N (1987) Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 107: 25–30

Connors JM, Klimo P, Voss N, Fairey RN, Jackson S (1988) Testicular lymphoma: Improved outcome with early brief chemotherapy. J Clin Oncol -6: 776–781

Czuczman MS, Grillo-Lopez AJ, White CA et al. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1):268–276-76

Dalla-Favera R, Ye BH, Lo CF et al. (1994) Identification of genetic lesions associated with diffuse large-cell lymphoma. Ann Oncol 5 [Suppl 1]: 55–60

Dana BW, Dahlberg S, Nathwani BN et al. (1993) Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol11(4): 644–651

Dave SS, Fu K, Wright G et al. (2006) Molecular Diagnosis of Burkitt’s Lymphoma. N Eng J Med 354: 2431‒2442 Dave SS, Wright G, Tan B et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of

tumor-infiltrating immune cells. N Eng J Med 351: 2159‒2169 Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R (1998) Anti-idiotype antibodies can induce long-term

complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 92: 1184–1190 De Angelo DJ, Yu D, Johnson JL et al. (1980) Nelarabine induces complete remissions in adults with relapsed or

refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study. Blood 109: 136‒142

De Jong D, Koster A, Hagenbeek A et al. (2009) Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94(1): 70‒77

De Jong D. (2005) Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 23: 6358‒6363

De Leval L, Rickman DS, Thielen C et al. (2007) The gene expression profile of nodal peripheral T cell lymphoma demonstrates a molecular link between angioimmunoblastic T cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109: 4952‒4963

de Mascarel A, Dubus P, Belleannee G, Megraud F, Merlio JP. (1998) Low prevalence of monoclonal B cells in Helicobacter pylori gastritis patients with duodenal ulcer. Hum Pathol 29(8): 784‒790

DeAngelis LM (2001) Brain tumors. N Engl J Med 344: 114–123 DeAngelis LM, Yahalom J, Thaler HT, Kher U (1992) Combined modality therapy for primary CNS lymphoma. J Clin

Oncol 10: 635–643 Deconinck E, Foussard C, Milpied N et al. (2005) High-dose therapy followed by autologous purged stem-cell

transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105(10): 3817‒3823

De Sanjose S, Benavente Y, Vajdic CM et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls form the international Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-458

DeVita VT, Hubbard JM, Longo DL (1987) The chemotherapy of6269 controls form the lymphomas: looking back, moving forward the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47: 5819–5824international Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-458

Dhedin N, Giraudier S, Gaulard P et al. (1999) Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 107: 154–161

Di Nicola M, Carlo-Stella C, Mariotti J et al. (2004) High response rate and mageable toxicities with an intense, short-term chemotherapy programme for Burkitt’s lymphoma in adults. Br J Haematol 126:815-820

Dierlamm J, Baens M, Wlodarska I et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p associated with mucosa-associated lymphoid tissue lymphomas. Blood 93: 3601–3609

Dierlamm J, Pittaluga S, Wlodarska I et al. (1996) Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 87: 299–307

Dierlamm J, Stefanova M, Wlodarska I et al. (2000a) Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: An interphase fluorescence in situ hybridization study. Cancer Genet Cytogenet 120: 1–5

Dierlamm J, Wlodarska I, Michaux L et al. (2000b) Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol 18: 1–13

Donato V, Iacari V, Zurlo A et al. (1998) Radiation therapy and chemotherapy in the treatment of head and neck extranodal non-Hodgkin’s lymphoma in early stage with a high grade of malignancy. Anticancer Res 18: 547–554

Donnellan R, Chetty R (1998) Cyclin D1 and human neoplasia. Mol Pathol 51: 1–7 Dragosics B, Bauer P, Radaszkiewicz T (1985). Primary gastrointestinal non-Hodgkin’sHodgkin's lymphomas. A

retrospective clinicopathologic study of 150 cases. Cancer 1985;55: (5):1060–1073 Dreger P, Martin S, Kuse R et al. (2000) The impact of autologous stem cell transplantation on the prognosis of

mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 1: 87–94 Dreyling M, Lenz G, Hoster E et al. Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous

Stem Cell Transplatation in First Remission significantly prolongs Progession-Free Survival in Mantle Cell Lymphoma – Results of a Prospective Randomized Trial of the European MCL Network. Blood 2005 105: 2677-2684

Dreyling M, Trümper L, von Schilling C, Rummel M, Holtkamp W, Waldmann A, Wehmeyer J, Freund M (2007) Results of an national consensus workshop: therapeutic algorithm in patients with follicular lymphoma – role of radioimmunotherapy. Ann Hematol 86: 81-7

Dreyling M, Weigert O, Hiddemann W: Current treatment standards and future strategies in mantle cell lymphoma. Ann Onc 2008, 19 (suppl 4): iv41-44

Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037

Du M, Diss TC, Xu C, Peng H, Isaacson PG, Pan L (1996) Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leuk 10: 1190–1197

Du MQ, Diss TC, Dogan A et al. (2000) Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa. J Pathol 192: 488–493

Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20: 5623–5637

Eck M, Schmausser B, Greiner A, Muller-Hermelink HK (2000). Helicobacter pylori in gastric mucosa-associated lymphoid tissue type lymphoma. Recent Results Cancer Res 2000;156: (10):9–-18

Economopoulos T, Fountzilas G, Kostourou A et al. (1998) Primary extranodal non Hodgkin’s lymphoma of the head and neck in adults: a clinicopathological comparison between tonsillar and non tonsillar lymphomas. (Hellenic co-Operative Oncology Group). Anticancer Res 18: 4655–4660

Efremov DG, Ivanovski M, Siljanovski N et al. (1996) Restricted immunoglobulin Vh region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood 87: 3869–3876

Ekström SK, Vajdic CM, Falster M, et al. (2008). Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes. A pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038

El Gnaoui T, Dupuis J, Belhadj K et al.(2007) Rituximab, gemcitabine and oxaliplatin : an effecitve salvage regimen for patients with relapsed or refractory B-cell lymphoma not candiadtes for high-dose therapy. Annals Oncol 18(8): 1363‒1368

Elstrom RL, Leonard JP, Coleman M, Brown RKJ (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19:1770‒1773

Elenitoba-Johnson KS, Jaffe ES (1997) Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 14: 35–47

Engelhard M (2001) Therapy of low grade NHL in early stages: Report from the UICC high level workshop. Ann Hemat 80 [Suppl 3]: B13–15

Engelhard M, Brittinger G, Dornoff W et al. (1996) High grade B-cell non-Hodgkin’s lymphomas: Kiel classification is a significant prognostic factor. Ann Oncol 7: S27

Engelhard M, Meusers P, Brittinger G, Theml H (1991) Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 2: 177–181

Falini B, Pileri S, Zinzani PL et al. (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93: 2697–2706

Fanin R, Silvestri F, Geromin A et al. (1996) Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/– radiotherapy) and autologous bone marrow transplantation. Blood 87: 1243–1248

Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 2005;128(6):1579-605 Farinha P, Gascoyne RD: Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol

23:6370-8, 2005 Fernandez V, Hartmann E, Ott G, Campo ES, Rosenwald A (2005) Pathogenesis of mantle cell lymphoma: all

oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 10: 6364‒6369

Ferrer A, Bosch F, Villamor N et al: Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135-141

Ferreri AJ, Dolcetti R, Dognini GP et al: Chlamydophila psittaci is visable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int J. Cancer 2008; 123: 1089-1093

Ferreri AJ, Dognini GP, Ponzoni M et al. (2008) Chlamydia-psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. Ann Oncol 19(1):194‒195

Ferreri AJ, Ponzoni M, Dognini GP et al. (2006) Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. Ann Oncol 17:1721–1722

Feugier P, van Hoof A, Sebban C et al. (2005) Long-term results of the R-CHOP study in the treatment of elderly patinets with with difuse large B -cell lymphoma: a study of the Groupe d’Etude des Lymphomes de lÀdulte. J Clin Oncol 25:787-92

Filipovich AH, Mathur A, Kamat D, Shapiro RS (1992) Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 52 [Suppl 19]: 5465s–5467s

Fischbach W, Göbeler ME, Ruskone-Fourmestraux A, et al. (2007) Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy experience from a large international series. Gut 56: 1685-1687

Fischbach W, Goebeler-Kolve ME et al. (2004) Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 53(1):34‒37

Fisher RI, Bernstein SH, Kahl BS et al: Multicenter Phase II Study of Bortezomib in Patients with Relapsed of Refractory Mantle Cell Lymphoma. J. Clin Oncol 2006: 24 (30): 4867-74

Fisher RI, Dana BW, LeBlanc M et al. (2000) Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 18: 2010–2016

Fisher RI, DeVita VT, Hubbard SM et al. (1983) Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304–309

Fisher RI, Gaynor ER, Dahlberg S et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–1006

Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin`s lymphomas. J Clin Oncol: 7565-73

Fisher RI, Longo DL, DeVita VT, Hubbard SM, Miller TP, Young RC (1991) Long-term follow up of ProMACE-CytaBOM in non-Hodgkin’s lymphomas. Ann Oncol 2: S33–S35

Fna M, Tani M , Stefoni V et al. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leuk Lymphoma 48:2167‒2171

Fonseca R, Habermann TM, Colgan JP et al. (2000) Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 88: 154–161

Foran JM, Rohatiner AZ, Coiffier B et al. (1999) Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17: 546–553

Forstpointner R, Dreyling M, Repp R et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10): 3064‒3071

Fossa A, Santoro A, Hiddemann W et al. (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 17: 3786–3792

Freedman A, Neuberg D, Mauch P et al. (1997) Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 90: 4996–5001

Freedman AS, Gribben JG, Nadler LM (1998a) High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin’s lymphoma. Leuk Lymphoma 28: 219–230

Freedman AS, Neuberg D, Gribben JG et al. (1998b) High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 16: 13–18

Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94(10): 3325‒3333

Gaidano G, Hauptschein RS, Parsa NZ et al. (1992) Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80: 1781–1787

Gallamini A, Zaja F, Gargantini L et al. (2005) CHOP chemotherapy plus Campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL) Blood 106:935a

Geisler CH, Kolstad A, Laurell A et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693

Ghielmini M, Schmitz SF, Cogliatti S et al: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin Oncol 2005; 23: 705

Gianni AM, Bregni M, Siena S et al. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290–1297

Giordano TP, Henderson L, Landgren O et al. (2007) Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297:2010-2017

Giralt S, Estey E, Albitar M et al. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531–4536

Gisselbrecht C, Gaulard P, Lepage E et al. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92: 76–82

Gisselbrecht C, Glass B, Mounier N et al. (2008) R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation : CORAL Study. Blood 110: 11

Glas AM, Kersten MJ, Delahaye LJ et al. (2005) Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105(1):301‒307

Glass B, Klöss M, Reiser M et al. (2006) Dose.escalated CHOP plus etoposide (Mega CHOEP) followed by repeated stemm dell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107:3058-64

Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rates. Cancer Treatment Reports 63: 1727–1733

Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of non cross-resistant chemotherapy. Cancer Treatment Reports 66: 439

Gopal AK, Rajendran JG, Petersdorf SH et al. (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99: 3158–3162

Gospodarowicz MK, Pintilie M, Tsang R et al. (2000) Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience. Recent Res Cancer Res 156: 108‒115

Giordano TP, Henderson L, Landgren O et al. (2007). Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297: 2010-2017

Gospodarowicz MK, Pintilie M, Tsang R et al. (2000) Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience. Recent Results Cancer Res 156(10): 108‒115

Goy A, Stewart J, Barkoh BA et al. (2006) The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. Cancer;108(1):10‒20

Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ (1987) Expression of bcl-2 and bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80: 1512‒1515

Greb A, Bohlius J, Trelle S et al. (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – results of a comprehensive meta-analysis. Cancer Treatment Reviews 33(4):338-346

Greiner A, Knorr C, Seeberger H, Schultz A, Muller-Hermelink HK (2000) Tumor biology of mucosa-associated lymphoid tissue lymphomas. Recent Res Cancer Res;156 (10):19–26

Gribben JG, Freedman AS, Neuberg D et al. (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525–1533

Gribben JG, Saporito L, Barber M et al. (1992) Bone marrows of non-Hodgkin’s lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 80: 1083–1089

Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. JNCI 92: 1240–1251

Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259–268

Ha CS, Cabanillas F, Lee MS et al. (1997) Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report. ClinClinical Cancer Res Research 3(2): 215–219

Haas R, Brittinger G, Meusers P et al. (1996) Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 10: 1975–1979

Haas R, Moos M, Karcher A et al. (1994) Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin’s lymphoma. J Clin Oncol 12: 1685–1692

Habermann T, Weller E, Morrison VA et al. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large cell lymphoma. J Clin Oncol 24: 3121-27

Haedicke W, Knorr C, Muller-Hermelink HK, Greiner A (1997) Receptor analysis of idiotype antibodies derived from MALT type B-cell lymphoma hybridomas. Hum Antibodies 8: 33–36

Hagenbeek A, Carde P, Meerwaldt JH et al. (1998) Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 16: 41–47

Hagenbeek A, Gadeberg O, Johnson P et al. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111(12): 5486‒5495

Hainsworth JD, Burris HA III, Morrissey LH et al. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052–3056

Haioun C, Besson C, Lepage E et al. (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol 11: 685–690

Haioun C, Itti E, Rahmouni A e al. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376-1381

Haioun C, Lepage E, Gisselbrecht C et al. (1994) Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin’s lymphoma in first complete remission: a study of 466 patients. J Clin Oncol 12: 2543–2551

Haioun C, Lepage E, Gisselbrecht C et al. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH87–2. J Clin Oncol 15: 1131–1137

Han HS, Escalon MP, Hsiao B et al. (2009) High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol epub

Hanna E, Wanamaker J, Adelstein D, Tubbs R, Lavertu P (1997) Extranodal lymphomas of the head and neck. A 20-year experience. Arch Otolaryngol Head Neck Surg 123: 1318–1323

Hans CP, Weisenburger DD, Vose JM et al. (2003) A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101(6):2363‒2367

Harris NL, Jaffe ES, Diebold J et al. (1999) The World Health Organization classification of neoplastic disease s of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10: 1419–1432

Harris NL, Jaffe ES, Stein H et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84: 1361–1392

Harris S, Wilkins BS, Jones DB (1996). Splenic marginal zone expansion in B-cell lymphomas of gastrointestinal mucosa-associated lymphoid tissue (MALT) is reactive and does not represent homing of neoplastic lymphocytes. J Pathol179 (1): 49–53

Hartge P, Devesa SS, Grauman D, Fears TR, Fraumeni JF Jr (1996) Non-Hodgkin’s lymphoma and sunlight. J Natl Cancer Inst 88: 298–300

Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 7 [Suppl 4]: 95–98

Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ (1991) Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 253: 79–82

Havemann K, Köppler H, Löffler M et al. (1993) Integratives Konzept zur Behandlung hochmaligner Non-Hodgkin-Lymphome. 1st edn. z, Marburg Homburg. [Treatment of hematological malignancies with monoclonal antibodies]

Heinemann V, Hiddemann W (2001) Altersdifferenzierte Therapie maligner Erkrankungen. Internist 41: 544–552 Hellmig S, Fischbach W, Goebeler-Kolve ME et al. (2005a) Association study of a functional Toll-like receptor 4

polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 46(6): 869‒872

Hellmig S, Vollenberg S, Goebeler-Kolve ME et al. (2004b) IL-1 gene cluster polymorphisms and development of primary gastric B-cell lymphoma in Helicobacter pylori infection. Blood 104(9): 2994‒2995

Hermine O, Lefrere F, Bronowicki JP et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347(2): 89‒94

Herold M, Haas A, Srock S et al. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25(15): 1986‒1992

Herrlinger U, Kuker W, Platten M, Dichgans J, Weller M (2002a) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58: 1573–1574

Herrlinger U, Schabet M, Brugger W et al. (2002b) German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of singleagent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51: 247–252

Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M. Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma. J Clin Oncol 2009 27 (4): 511-8

Hicks LK, Woods A, Buckstein R et al. (2008) Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 24

Hiddemann W, Griesinger F, Unterhalt M (1998a) Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am 4 [Suppl 2]: S13–S18

Hiddemann W, Kneba M, Dreyling M et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood;106(12): 3725‒3732

Hiddemann W, Longo DL, Coiffier B et al. (1996) Lymphoma classification – The gap between biology and clinical management is closing. Blood 88: 4085–4089

Hiddemann W, Sack H, Unterhalt M (1997) Aktueller Stand in der Therapie von follikulären Keimzentrumslymphomen und Mantelzell-Lymphomen. Internist 38: 122‒134

Hiddemann W, Unterhalt M, Herrmann R et al. (1998b) Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle -center lymphomas: Resultsresults of a prospective comparative analysis of the German low-grade lymphoma study group.Low-Grade Lymphoma Study Group. J Clin Oncol16(5): 1922–1930

Hiddemann W, Unterhalt M, Sack H (1997) Current status of therapy of follicular germ center lymphoma and mantel cell lymphoma. Internist (Berl) 38: 122–134

Hjalgrim H, Askling J, Sorensen P et al. (2000) Risk of Hodgkin’s disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 92: 1522–1528

Hochberg FH, Tabatabai G (2001) Therapy of PCNSL at the Massachusetts General Hospital with high dose methotrexate and deferred radiotherapy. Ann Hematol 80 [Suppl 3]: B111–112

Hoederath A, Stuschke M, Lampka E, Sack H (1996) Studiengruppe NHL – frühe Stadien: Strahlentherapie primär extranodaler Non-Hodgkin-Lymphome der Kopf-Hals-Region. Ergebnisse einer prospektiven multizentrischen Studie. Strahlenther Onkol 172: 356–366

Hölscher G, Schmidt S, Dreyling M (2008): Epidemiologie maligner Lymphome. In Manual maligne Lymphome (Ed. M. Dreyling), Zuckschwerdt Verlag München

Hoelzer D, Baur KH, Giagounidis A et al. (2003) Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, mature B-ALL and other high-grade B-NHL. Blood 102:236

Hoelzer D, Gökbget N, Digel W et al. (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated accordinfg to protocols for acute lymphoblastic leukemia. Blood 99: 4379‒4385

Hochster HS, Weller E, Gascoyne RD et al. (2005) Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 99: 4379‒4385

Horning S, Rosenberg S. The natural history of initially untertreated low-grade non-Hodgkin´s lymphoma. New England Journal of Medicine 1984;311:1471‒1475

Horning SJ (1996) Purine analogs in marginal-zone lymphomas. Ann Oncol 7 [Suppl 6]: S21–S26 Horning SJ, Negrin RS, Hoppe RT et al. (2001) High-dose therapy and autologous bone marrow transplantation for

follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97: (2):404–409 Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N

Engl J Med 311: 1471–1475 Horning SJ (2008) Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 26(28):

4537‒4538 Horning SJ. (1996) Purine analogs in marginal-zone lymphomas. Ann Oncol 7(3) [Suppl 6]:S21‒26 Horsman D, Gascoyne R, Klasa R, Coupland R (1992) t (11;18)(q21;q 21.1): a recurring translocation in lymphomas

of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer 4: 183–187 Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M,

Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen W, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008 111(2): 558-65

Howard OM, Gribben JG, Neuberg DS et al. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20: 1288–1294

Hsi ED, Mirza I, Lozanski G et al. (2004) A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med;128(8):863-8

Hsu FJ, Benike C, Fagnoni F et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52–58

Hsu FJ, Levy R (1995) Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 86: 3072–3082

Hu S, Du MQ, Park SM et al. (2006) cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest;116(1):174-81

Hummel M, Bentink S, Berger H et al. (2006) A biologic definition of Burkitt’s Lymphoma from transcriptional and genomic profiling. N Eng J Med 354: 2419‒2430

Hummel M, Oeschger S, Barth TF et al. (2006) Wotherspoon criteria combined with B cell clonality analysis by advanced polymerase chain reaction technology discriminates overt gastric marginal zone lymphoma from chronic gastritis. Gut 55: 782‒787

Hummel M, Stein H (2000) Clinical relevance of immunoglobulin mutation analysis. Curr Opin Oncol 12: 395–402 Husain A, Roberts D, Pro B et al. (2007) Meta-analyses of the association between Chlamydia psittaci and ocular

adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer: 110: 809‒815 IARC (2001) Tumours of haemotopoietic and lymphoid tissue. 1 ed. IARC Press, Lyon IARC (2008) Tumours of haemotopoietic and lymphoid tissue. 2 ed. IARC Press, Lyon Inoges S, Rodriguez-Calvillo M, Zabalegui Net al. (2006) Clinical benefit associated with idiotypic vaccination in

patients with follicular lymphoma. J Natl Cancer Inst 98(18): 1292‒1301 Isaacson PG (1996). Splenic marginal zone lymphoma. Blood 1996;88: (2):751–752-2 Isaacson PG, Du MQ (2004) MALT lymphoma: from morphology to molecules. Nat Rev Cancer 4(8): 644‒653 Isaacson PG, Spencer J. Malignant lymphoma of mucosa- associated lymphoid tissue. Histopath 11: 445–462Journal

of Clinical Pathology 1987;48:395-397 Isaacson PG, Wright DH (1983) Malignant lymphoma of mucosa-associated lymphoid tissue. Cancer 52:1410‒1416

Jaffe ES, Diebold J, Harris NL (1999a) Burkitt’s lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Blood 93: 1124

Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK (1999b) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111 [Suppl 1]: S8–12

Janicek M, Kaplan W, Neuberg D et al. (1997) Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin’s lymphoma treated with highdose CHOP chemotherapy. J Clin Oncol 15: 1631–1637

Janik JE, Dunleavy K, Pittaluga S et al. (2005) A pilot trial of Campath-1H and dose adjusted EPOCH in CD52 expressing aggressive T-cell malignancies. Blood 106:936a

Ji W, Qu GZ, Ye P et al. (1995) Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. Cancer Res 55: 2876–2882

Johnson TA, Press OW (2000) Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 79: 175–182

Joos S, Kupper M, Ohl S et al. (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60: 549‒552

Joos S, Otano-Joos MI, Ziegler S M et al. (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87: 1571–1578

Juckett M, Rowlings P, Hessner M et al. (1998) T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin’s lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 21: 893–899

Juliusson G, Liliemark J (1995) Which is the highest tolerable dose of cyclophosphamide and etoposide with doxorubicin and G-CSF but without stem cells in poor risk non-Hodgkin’s lymphoma? Blood 86: 816a

Juweid ME, Wiseman GA, Vose JM et al. (2005) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661

Kaiser U, Uebelacker I, Birkmann J, Havemann K, for the DSHNHL (2002) Randomized Study to Evaluate the Use of High Dose Therapy as Part of Primary treamtnet for „Aggressive“ Lymphoma. J Clin Oncology 22: 4413‒4419

Kalla J, Stilgenbauer S, Schaffner C et al. (2000) Heterogeneity of the API-MALT1 gene rearrangement in MALT-type lymphoma. Leukemia 26: 1967‒1974

Kaminski MS, Estes J, Zasadny KR et al. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259–1266

Kaminski MS, Fenner MC, Tuck M et al. (2005) Phase I/II trial results of 131-I-ANTI-B1 non-myeloablative radioimmunotherapy for refractory B-cell lymphoma. Proceedings ASCO 15: 414131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5): 441‒449

Kasamon YL and Swinnen LJ (2004) Treatment advances in adult Burkitt lymphoma and leukaemia. Curr Opin Oncol 16:429-435

Katz S, Downs TD, Cash HR, Grotz RC (1970) Progress in development of the index of ADL. Gerontologist 10: 20–30

Kelemen LE, Cerhan JR, Lim ut, et al. (2006). Vegetables, fruit, and antioxidant-related nutrients and risk of non-Hdogkin lymphoma : a National Cancer Institute-Surveillance, Epidemiology, and End Results population-based case-control study. Am J Clin Nutr 83: 1401‒1410

Kelsey S M, Newland AC, Hudson GV, Jelliffe AM (1994). A British National Lymphoma Investigation randomisedrandomized trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkin´s lymphoma. Med Oncol 11: 19–25

Khouri IF, Lee MS, Saliba RM et al. (2003) Nonablative allogeneic stem cell transplantation for advanced/ recurrent mantle cell lymphoma. J Clin Oncol 21: 4407-12

Khouri IS, McLaughlin P, Saliba Rm et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood 2008; 111:5530-5536

Khouri I, Przepiorka D, Besien KV et al. (1997) Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versushost-disease. Br J Haematol 97: 466–473

Kimby E, Bjorkholm M, Gahrton G et al. (1994) Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin’sHodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994;5 [Suppl 2]: :67–-71

Kipps TJ, Carson DA (1993) Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 81: 2475–2487

Klimo P, Connors JM (1987). Updated clinical experience with MACOP-B. Semin Hematol 1987;24 [(2 Suppl 1]: ):26–-34

Knauf WU, Guckel F, Dohner H et al. (1991) Detection of bone marrow infiltration by non-Hodgkin’s lymphoma–comparison of histological findings, analysis of gene rearrangements, and examination by magnetic resonance imaging. Klin Wschr 69: 345–350

Knowles DM (1999) Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 12: 200–217 Koch P, Grothaus-Pinke B, Hiddemann W et al. (1997). Primary lymphoma of the stomach: three-year results of a

prospective multicenter study. The German Multicenter Study Group on GI-NHL. Ann Oncol 1997;8 [Suppl 1]: (4):85–88-8

Koch P, Probst A, Berdel WE et al. (2005) Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23(28): 7050‒7059

Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. [see comments]. Blood 86(5): 2041–2050

Köppler H, Pflüger KH, Eschenbach I et al. (1989) CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin’s lymphomas: a phase II multicentre study. Br J Cancer 60: 79–82

Korfel A, Finke J, Schmidt-Wolf I, Thiel E (2001) 5. Report on workshop: Primary CNS lymphoma. Ann Hematol 80 [Suppl 3]: B20–23

Korsmeyer SJ (1992a) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879–886 Korsmeyer SJ (1992b) Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu

Rev Immunol 10: 785–807 Korsmeyer SJ (1999) BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59: 1693s–1700s Kouroukis T, Meyer RM (2001) Treatment strategies in elderly patients with aggressive histology NHL. Ann Hematol

80 [Suppl 3]: B86–88 Krishnan A, Nadamanee A, Fung HC et al. 2008 Phase II trial of transplantation regimen of Yttrium-90 ibritumomab

tiuxetan and high-dose chemotherapy in patients with non-Hodgkin`s lymphoma. J Clin Oncol 26:90-95 Kroger N, Hoffknecht M, Kruger W N et al. (2000) Allogeneic bone marrow transplantation for refractory mantle cell

lymphoma. Ann Hematol 79: 578–580 Kuo SH, Chen LT, Wu MS et al. (2008) Long-term follow-up of gastrectomized patients with mucosa-associated

lymphoid tissue lymphoma: need for a revisit of surgical treatment. Ann Surg;247(2):265-9 Kuse R, Sonnen R (1998) Langzeitergebnisse der Behandlung hochmaligner Non-Hodgkin-Lymphome im hohen

Lebensalter (>70 Jahre). Dtsch Med Wschr 123: 205–211 Lagrange JL, Ramaioli A, Theodore CH et al. (2001) Non-Hodgkin’s lymphoma of the testis: a retrospective study of

84 patients treated in the French anticancer centres. Ann Oncol 12: 1313–1319 Lamant L, de Reynies A, Duplantier MM et al. (2007) Gene expression profiling of systemic anaplastic large cell

lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109: 2156-2164

Lambrechts A, Hupkes P, Dorssers L et al. (1994) Clinical significance of t (14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin’´s lymphoma during first remission. J Clin Oncol 12: 1541–1546

Lambrechts AC, Hupkes PE, Dorssers LC et al. (1992) BCL-2 initiates a new category of oncogenes: regulators of cell deaths. Blood 80: 879‒886

Lee A, O’RourkeO'Rourke J, Enno A (2000). Gastric mucosa-associated lymphoid tissue lymphoma: implications of animal models on pathogenic and therapeutic considerations – --mouse models of gastric lymphoma. Recent Results Cancer Res 2000;156: (10):42–-51

Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89 (10); 1275-6

Lefrere F, Delmer A, Suzan F et al. (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leuk 16: 587–593

Lefrere F, Hermine O, Belanger C et al. (2000) Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 14(4): 573‒575

Leich E, Haralambieva E, Zettl A et al. (2007) Tissue microarray-based creening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. J Pathol, epub ahead of print

Lejeune M, Alvaro T (2009) Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma. Haematologica 94(1):16-21

Lennert K, Feller A. (1990) Histopathologie der Non Hodgkin Lymphome. 2 Auflage ed. Berlin Heidelberg New York: Springer

Lenz G, Dreyling M, Hoster E et al. (2005) Immuno-chemotherapy with rituximab and CHOP significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma – results of an prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992

Lenz G, Dreyling M, Schiegnitz E et al. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104(9): 2667‒2674

Lenz G, Dreyling M, Schiegnitz E et al. (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22(24): 4926‒4233

Lenz G, Wright G, Dave SS, et al. (2008) Stromal signatures in large B-cell lymphomas. N Engl J Med 2008; 359:2313-23

Leonard JP, Schuster SJ, Emmanouilides C et al. (2008) Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113(10): 2714‒2723

Levine EG, Juneja S, Arthur D et al. (1990) Sequential karyotypes in non-Hodgkin lymphoma: their nature and significance. Genes Chromosom Cancer 1: 270–280

Libson E, Polliak A, Bloom RA (1994) Value of lymphangiography in the staging of Hodgkin lymphoma. Radiology 193: 757–759

Liebowitz D (1998) Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338: 1413–1421

Liliemark J, Martinsson U, Cavallin-Stahl E et al. (1998) Cladribine for untreated or early low-grade non-Lim U, Morton LM, Subar AF, et al. (2007). Alcohol, smoking, and body size in relation to incident Hodgkin’s lymphoma. Leuk Lymphoma 30: 573–581

Lim, U, Morton LM, Subar AF et al. (2007) Alcohol, smoking, and body size in relation to incident Hodgkin`s and non-Hodgkin`s lymphoma risk. Am J Epidemiol 166:697-708

Lim U, Wang SS, Hartge P et al (2207) Gene-nutricient interactions of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma. NCI-SEER case-control study. Blood 109:3050-3059

Linet MS, McLaughlin JK, Hsing AW et al. (1992) Is cigarette smoking a risk factor forand non-Hodgkin’s lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study. Leuk Res 16: 621–624risk. Am J Epidemiol 166: 697-708

Lister TA, Crowther D, Sutcliffe SB et al. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’sHodgkin's disease: Cotswolds meeting. J Clin Oncol 7: (11):1630–1636-6

Lister TA, Crowther TA, Sutcliffe SB (1989)Lim U, Wang SS, Hartge P, et al. (2007). Gene-nutricient interactions of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma. NCI-SEER case-control study. Blood 109: 3050-3059

Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al. (2001) Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357: 39–40

Liu H, Ye H, Ruskone-Fourmestraux A et al. (2002) T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology;122(5):1286-94

Liu Y, Hernandez AM, Shibata D, Cortopassi GA (1994) BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 91: 8910–8914

Lones MA, Perkins SL, Sposto R et al. (2000) Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J Clin Oncol 18: 3845–3853

Long GD, Amylon MD, Stockerl-Goldstein KE et al. (1997) Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 3: 324–330

Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278: 1059–1064 Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. (1998) The clinical significance of molecular responseremission

in indolent follicular lymphomas. Blood 91: 2955–2960 Lucas PC, Yonezumi M, Inohara N et al. (2001) Bcl10 and MALT1, independent targets of chromosomal

translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 276(22):19012‒9

Luppi M, Grazia FM, Bonaccorsi G et al. (1996) Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leuk 10: 351–355

Luppi M, Longo G, Ferrari MG et al. (1996) Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 94: 373–375

MacManus M, Hoppe R (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow- up study of patients treated at in Stanford University. J Clin Oncol 14: 1282–1290

Maes B, Baens M, Marynen P, Wolf-Peeters C (2000) The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type. Ann Oncol 11: 521–526

Magrath IT (1998) Management of high-grade lymphomas. Oncology (Huntingt) 12: 40–48 Maloney DG, Grillo LA, White CA et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in

patients with relapsed lowgrade non-Hodgkin’s lymphoma. Blood 90: 2188–2195 Manns A, Hisada M, La Grenade L (1999) Human T-lymphotropic virus type I infection. Lancet 353: 1951–1958 Marcus R, Imrie K, Belch A et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment

for advanced follicular lymphoma. Blood 105(4): 1417‒1423 Marcus R, Imrie K, Solal-Celigny P et al. (2008) Phase III study of R-CVP compared with cyclophosphamide,

vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 16: 2825–2833 26(28):4579-86

Mauch P (2001) Follicular non-Hodgkin's lymphoma: the role of radiation therapy. Ann Hematol 80 [Suppl 3]:B63-65 McKelvey EM, Gottlieb JA, Wilson HE (1976) Hydroxydaunomycin (adriamycin) combination chemotherapy in

malignant lymphomas. Cancer 38: 1484–1493 Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, et al. (2005) Clinical activity of rituximab in

gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 5: 867–8742

Mandigers CM, Meijerink JP, Mensink EJ et al. (2001) Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 98(4): 940‒944

McLaughlin P, Fuller LM, Velasquez WS et al. (1987) Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 9: 339–347

McLaughlin P, Grillo-Lopez AJ, Link BK et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8): 2825‒2833

McLaughlin P, Hagemeister FB, Romaguera JE et al. (1996) Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14(4):1262-8

Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40: 761–768

Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A: 1753–1757

Melnyk A, Rodriguez A, Pugh WC, Cabannillas F (1997) Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 89: 4514–4520

Melzner I, Bucur Aj, Bruderlein S, et al. (2005) Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB1 mediastinal lymphoma line. Blood 105: 2535-2542

Meusers P, Engelhard M, Bartels H et al. (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7: 365–380

Mateo M, Mollejo M, Villuendas R et al. (1999) 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 154(5): 1583‒1589

Meyer RM, Gyger M, Langley R, Lesperance B, Caplan SN (1998) A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 30: 591–600

Meyer RM, Hryniuk WM, Goodyear MDE (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin’s lymphoma. J Clin Onkol 9: 339‒347

Meyer RM, Browman GP, Samosh ML et al. (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J Clin Oncol 13(9): 2386‒2393

Miehlke S, Meining A, Morgner A et al. (1998) Frequency of vacA genotypes and cytotoxin activity in Helicobacter pylori associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Clin Microbiol 1998;36: (8):2369–-2370

Miller TP, Dahlberg S, Cassady JR et al. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339: 21–26

Miller TP, LeBlanc M, Spier C et al. (2001) CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas: update of the Southwest Oncology Group randomized trial. Blood 98:724a

Milligan DW, Ruiz De Elvira MC, Kolb HJ et al. (1999) Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol106 (4):1020–1026

Moog F, Bangerter M, Kotzerke J (1998) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16: 603–609

Morgan G, Vornanen M, Puitinen J et al. (1997) Changing trends for the incidence of non-Hodgkin’s lymphoma in Europe. Ann Oncol 8: S49–S54

Morris SW, Kirstein MN, Valentine MB et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263: 1281–1284

Morris SW, Kirstein MN, Valentine MB et al. (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 267: 316–317

Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, Hess G, Stein H, Kalmus J, Marcuse R. (2007)Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation Blood 110 (1):54-8

Morton LM, Bernstein L, Wang SS et al. (2007) Hair de use, genetic variation in N-acetyltransferase 1 (NAT1) and 2. Results during the treatment period 1972–1976 compared with the period 1964–1971. (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis 28: 1759‒1764

Morton LM, Wang SS, Devesa SS et al. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265-276

Moskowitz C, Hamlin PA, Horwitz SM et al. (2006) Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. Blood 108 (Nr. 11): 532 (Abstract)

Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78(2):206-9

Morschhauser F, Radford J, Van Hoof A et al. (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26(32): 5156‒5164

Musshoff K, Weidkuhn V, Bammert J, Felker HU (1985) [Diagnosis and therapy of Hodgkin's disease in Freiburg in Breisgau 1964 to 1976. 1. Report of the complete collective]. Strahlentherapie 161: 596–614

Nademanee A, Forman S, Molina A et al. (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106(8): 2896‒2902

Nakamura S, Matsumoto T, Jo Y et al. (2003) Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol 56(1): 36‒42

Nathwani BN, Anderson JR, Armitage JO et al. (1999) Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin’sHodgkin's Lymphoma Classification Project. J Clin Oncol 17(8): 2486–2492

NCI non-Hodgkin’s Classification Project Writing Committee (1985) Classification of non-Hodgkin’s lymphomas. Reproducibility of major classification systems. Cancer 55: 91–95

Nelson RA, Levine AM, Bernstein L (1998) Blood transfusions and the risk of intermediate- or high-grade non-Hodgkin’s lymphoma. J Natl Cancer Inst 90: 1742–1743

Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R (1988) Analysis of RAS oncogenes in human lymphoid malignancies. Proc Natl Acad Sci USA 85: 9268–9272

Neubauer A, Herrmann R (1989) Treatment of low malignancy non-Hodgkin lymphomas with recombinant interferon. Current status. Med Klin 84: 355–358. Interferon in der Therapie niedrig maligner Non Hodgkin Lymphome. Medizinische Klinik 84: 355‒359

Neubauer A, Thiede C, Morgner A et al. (1997) Cure of helicobacterHelicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissueMALT lymphoma. J Natl Cancer Inst 89: 1350–1355

Nickenig C, Dreyling M, Hoster E et al. (2006) CHOP improves Response Rates but not Survival and hat a lower Hematologic Toxicity as compared to MCP in Follicular and Mantle Cell Lymphomas – Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). Cancer 107 (5): 1014-22

O’Brien JP, O’Keefe PO, Alvarez A et al. (1995) The NHL-15 protocol for diffuse aggressive lymphomas: Two year median follow-up on the first 100 patients. Proceedings ASCO 1230

O’Reilly SE, Klimo P, Connors JM (1991) Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9: 741–747

Ohashi S, Segawa K, Okamura S et al. (2000) A clinicopathologic study of gastric mucosa-associated lymphoid tissue lymphoma. Cancer 88(10): 2210–2219

Okano M, Gross TG (2001) From Burkitt’s lymphoma to chronic active Epstein-Barr virus (EBV) infection: an expanding spectrum of EBV-associated diseases. Pediatr Hematol Oncol 18: 427–442

Ostrowski ML, Unni KK, Banks PM et al. (1986) Malignant lymphoma of bone. Cancer 58: 2646–2655 Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG, Müller-Hermelink HK (1997): Blastoid variants of

mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89: 1421‒1429

Ott G, Katzenberger T, Greiner A et al. (1997) The t (11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin’s lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 57: 3944–3948

Ott G, Katzenberger T, Lohr A et al. ((2002) Cytomorphologic, immunhisto-chemical and cytogenic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99: 3806-3812

Ott MM, Rosenwald A, Katzenberger T et al. (2000) Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities. Genes Chromosomes Cancer 28: 380–386

Passweg JR, Rowlings PA, Armitage JO et al. (1995) Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry – North America. Clin Transpl 117–127

Patel P, Hanson DL, Sullivan PS, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992‒2003. Ann Intern Med 148: 728-736

Paulli M, Strater J, Gianelli U et al. (1999) Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 30: 178–187

Pawson R, Dyer MJ, Barge R et al. (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15: 2667–2672

Pearce N, Bethwaite P (1992) Increasing incidence of non-Hodgkin’s lymphoma: occupational and environmental factors. Cancer Res 52: 5496s–5500 s

Pees HW, Radtke H, Schwamborn J, Graf N (1992) The BFM-protocol for HIV-negative Burkitt’s lymphomas and L-ALL in adult patients: a high chance for cure. Ann Hematol 79: 2520–2526

Pelosini M, Focosi D, Rita F et al. (2008) Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 87(5): 405‒412

Peterson BA, Petroni GR, Frizzera G et al. (2003) Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21(1): 5‒15

Pfreundschuh M, Schubert J, Ziepert M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressivew CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60) Lancet Oncol 9:105-16

Pfreundschuh M, Trümper L, Klöss M et al. (2001a) CHOEP (Chop + etoposide): The new standard regimen for younger patients with low risk (low LDH) aggressive non-Hodgkin’s lymphoma. Blood 97: 405

Pfreundschuh M, Trümper L, Österborg A et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trialby the MabThera International Trial (MInT) Group. Lancet Oncology 7:379‒392

Pfreundscuh M, Trümper L, Kloess M et al. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626‒33

Philip T, Guglielmi C, Somers R et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333: 1540–1545

Piccaluga PP, Agostinelli C, Califano A, et al. (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117: 823‒834

Piro LD, White CA, Grillo-Lopez AJ et al. (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory lowgrade or follicular non-Hodgkin’s lymphoma. Ann Oncol 10: 655–661

Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Brüggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling m, Hiddemann W, Siebert R, Dreger P, Kneba M. (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107: 2271-78

Press OW, Eary JF, Gooley T et al. (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96: 2934–2942

Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI; Southwest Oncology Group. (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24: 4143-9

Price CG, Meerabux J, Murtagh S et al. (1991a) The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 9: 1527–1532

Price CG, Rohatiner AZ, Steward W et al. (1991b) Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 2 [Suppl 2]: 141–145

Prior P (1985) Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med 78: 15–21 Qin Y, Greiner A, Trunk MJ, Schmausser B, Ott MM, Muller-Hermelink HK (1995) Somatic hypermutation in low-

grade mucosa-associated lymphoid tissue-type B-cell lymphoma. Blood 86: 3528–3534 Rabbitts TH (1991) Translocations, master genes, and differences between the origins of acute and chronic

leukemias. Cell 67: 641–644 Rabkin CS, Biggar RJ, Horm JW (1991) Increasing incidence of cancers associated with the human

immunodeficiency virus epidemic. Int J Cancer 47: 692–696 Radaszkiewicz T, Dragosics B, Bauer P. (1992) Gastrointestinal malignant lymphomas of the mucosa-associated

lymphoid tissue: factors relevant to prognosis. Gastroenterology 102(5): 1628‒1638 Raffeld M, Jaffe ES (1991) bcl-1, t (11;14), and mantle cell-derived lymphomas. Blood 78: 259–263 Ratei R, Matylis A, Krahl D et al. (2000) Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic

HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8. Leuk Lymphoma 40: 133–140

Reimer P, Rüdiger T, Geissinger E et al. (2009) Autologous stem-cell transplantation as first line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27:106‒113

Reyes F, Lepage E, Ganem G et al.(2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphom. N Engl J Med 346:1937‒1947

Rezvani AR, Storer B, Maris M et al. (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26(2): 211‒217

Ribera JM, Oriol A, Morgades M et al. (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immundeficieny virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 140: 411‒419

Rizvi MA, Evens AM, Tallmann MS et al. (2006) T-cell non-Hodgkin lymphoma. Blood 107: 1255‒1264 Robinson SP, Goldstone AH, Mackinnon S et al. (2002) Chemoresistant or aggressive lymphoma predicts for a poor

outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (13): 4310-6

Rodriguez MA, Jendiroba D, Cabanillas F et al. (1994) Characteristics of long term survivors treated with salvage chemotherapy for lymphomas. Blood 84: 647a

Roers A, Montesinos RM, Hansmann ML, Rajewsky K, Kuppers R (1998) Amplification of TCR-beta gene rearrangements from micromanipulated single cells: T cells rosetting around Hodgkin and Reed-Sternberg cells in Hodgkin’s disease are polyclonal. Eur J Immunol 28: 2424–2431

Roggero E, Zucca E, Pinotti G et al. (1995) Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122: 767–769

Rohatiner A. (1994) Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation. J Clin Oncol 12(12): 2521‒2523

Rohatiner AZ, Bassan R, Raimondi R et al. (2000) High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. Ann Oncol 11(8):1007‒1015

Rohatiner AZ, Gregory WM, Peterson B et al. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23(10): 2215‒2223

Rohatiner AZ, Johnson PW, Price CG et al. (1994) Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12: 1177–1184

Rohde D, Hansen H, Hafner M et al. (1992) Cellular localizations and processing of the two molecular forms of the Hodgkin-associated Ki-1 (CD30) antigen. The protein kinase Ki-1/57 occurs in the nucleus. Am J Pathol 140: 473–482

Romaguera JE, Fayad L, Rodriguez MA et al. (2005) High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. J Clin Oncol 23: 7013

Romaguera JE, Khouri IF, Kantarjian HM et al. (2000) Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39: 77–85

Rosenberg SA (1966) Report of the committee in the staging of Hodgkin’s disease. Canc Res 26: 1310 Rosenwald A, Wright G, Wiestner A et al.: (2003) The proliferation gene expression signature is a quantitative

integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. Feb;3(2):185-97 Rosse T, Olivier R, Monney L et al. (1998) Bcl-2 prolongs cell survival after Bax-induced releaserelase of cytochrome

C.c. Nature (Lond.) 391: 496–-499 Rübe C, Nguyen TP, Kloss M (2001) Consolidation radiotherapy to bulky disease in aggressive NHL. First results of

the NHL B-94 trial of the DSHNHL. Ann Hematol 80 [Suppl 3]: B84–B85

Rudolph B, Bayerdorffer E, Ritter M et al. (1997) Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? J Clin Oncol 15: 1104–1109

Rummel MJ, Al-Batran SE, Kim SZ et al. (2005) Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 23: 3383

Rummel MJ, von Gruenhagen U, Niederle N et al. (2007) Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas--first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 110:120a. Abstract 385

Sackmann M, Morgner A, Rudolph B et al. (1997) Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005;106(5):1831-8

Sackmann M, Morgner A, Rudolph B et al. (1997) Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. Gastroenterology 113: 1087–1090

Salles G, Mounier N, de Guibert S et al. (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112(13): 4824‒4831

Sano T (2000). Treatment of primary gastric lymphoma: experience in the National Cancer Center Hospital, Tokyo. Recent Results Cancer Res 2000;156: (10):104–107

Santini G, Salvagno L, Leoni P et al. (1998) VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 16: 2796–2802

Savio A, Franzin G, Wotherspoon AC et al: (1996) Diagnosis and posttreatment follow-up of Helicobacter pylori positive gastric lymphoma of mucosa-associated lymphoid tissue: Histology, polymerase chain reaction, or both? Blood;87:1255-1260

Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P (2000) Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 97: 2773–2778

Schechter NR, Portlock CS, Yahalom J (1998). Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16: (5):1916–1921-21

Schlegelberger B, Zwingers T, Harder L et al. (1999) Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group. Blood 94: 3114–3120

Schmits R, Glass B, Trümper L, Pfreundschuh M (2001) Therapeutic strategies for aggressive lymphoma: The trials of the DSHNHL. Ann Hematol 80 [Suppl 3]: B77–83

Schmits R, Trümper L (2001) Therapy of aggressive lymphoma in early stages: Report from the UICC workshop. Ann Hematol 80 [Suppl 3]: B16–19

Schmitz N, Dreger P, Glass B and Sureda A (2007) Allogenic transplantation in lymphoma: current status. Haematologica 92: 1533-1548

Schmitz N, Ziepert M, Nickelsen M et al. (2008) Mature T-/NK-cell lymphomas: prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL) Blood 2008

Schouten HC, Qian W, AgtheKvaloy S et al. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21): 3918‒3927

Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. (2006) Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the GELA. Blood

SEER (Surveillance, Epidemiology, and End Results Programm). SEER Stat Fact Sheets. http:{{www.seer.cancer.gov/statfacts/htlm

Seidemann K, Tiemann M, Schrappe M et al. (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97: 3699–3706

Senff NJ, Noordijk, Kim YH, et al. (2008);European Organisation for Research and Treatment of Cancer and International Society of Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112: 1600-1609

Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM (2000) BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13: 199–212

Shahab N, Doll DC (1999) Testicular lymphoma. Semin Oncol 26: 259–269 Shipp MA (1996) Can we improve upon the International Index? Ann Oncol 7: 11

Shipp MA, Abeloff MD, Antman KH et al. (1999) International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. Ann Oncol 10: 13–19

Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN (1995) High dose CHOP as initial therapy for patients with poor-prognosis aggressive Non-Hodgkin’s lymphoma: A dose-finding pilot study. J Clin Oncol 13: 2916–2923

Shipp MA, Ross KN, Tamayo P et al. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68–74

Siegert W, Nerl C, Agthe A et al. (1999b) Angioimmunoblastic lymphadenopathy type T-cell lymphoma: Prognostic impact of clinical observations and laboratory findings at presentation. Ann Oncol 6: 659–664

Siegert W, Nerl C, Engelhard M et al. (1999c) Peripheral T-cell non-Hodgkin’s lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert’s) lymphoma and T-zone lymphoma. Br J Haematol 87: 529–534

Skillings JR, Bramwell V, Nicholson RL, Prato FS, Wells G (1996) A prospective study of magnetic resonance imaging in lymphoma staging. Cancer 67: 1838–1843

Skinnider BF, Connors JM, Sutcliffe SB, Gascoyne RD (1999) Anaplastic large cell lymphoma: a clinicopathologic analysis. Hematol Oncol 17: 137–148

Skipper H (1971) Kinetic behavior versus response to chemotherapy. Natl Cancer Inst Monogr 34: 2–17 Slavin S, Nagler A, Naparstek E et al. (1998) Non-myeloablative stem cell transplantation and cell therapy as an

alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3): 756–763

Smalley RV, Andersen JW, Hawkins MJ et al. (1992) Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327: 1336–1341

Solal-Celigny P, Lepage E, Brousse N et al. (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med 329: 1608–1614

Solal-Celigny P, Roy P, Colombat P et al. (2004) Follicular lymphoma international prognostic index. Blood;104(5):1258‒1265

Solomon E, Borrow J, Goddard AD (1991) Chromosome aberrations and cancer. Science 254: 1153–1160 Sonnen R, Kuse R (1998) . [Long term results of treatment of highly-malignant non-Hodgkin lymphoma in the elderly

(70 years and older).)]. Dtsch Med Wschr Wochenschr 1998;123: (8):205–211 Sonneveld P, de Ridder M, van der Lelie H (1995) Comparison of doxorubicin and mitoxantrone in the treatment of

elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13: 2530–2539

Sparano JA, Wiernik PH, Leaf A, Dutcher JP (1993) Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin’s lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11: 1071–1079

Stansfield AG, Diebold J, Noel H et al. (1988) Updated Kiel Classification.classification Lancet 1: 292–2933; 1 (8581): 372

Starostik P, Patzner J, Greiner A, Schwarz S, Kalla J, Ott G et al. (2002) Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 99(1): 3‒9

Stein H, Foss HD, Durkop H et al. (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96: 3681–3695

Stein RS, Greer JP, Goodman S et al. (1999). High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 23: (3):227–233

Steward WP, Crowther D, McWilliam LJ et al. (1988) Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’sHodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61(3):441–447

Stilgenbauer S, Liebisch P, James MR et al. (1996) Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22. 3–923. 1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 93: 11837–11841

Stilgenbauer S, Schaffner C, Winkler D et al. (2000) The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 11 [Suppl 1]: 127–130

Stolte M, Eidt S. (1992) The ATM gene in the pathogenesisdiagnosis of mantle-cellearly gastric lymphoma. Ann Oncol 11 [Suppl 1]: 127–130Zeitschrift für Gastroenterologie;29:6-10

Strauss SJ, Morschhauser F, Rech J et al. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24(24): 3880‒3886

Streubel B, Simonitsch-Klupp I, Müllauer L, et al. (2004) Variable frequencies of MALT lymphoma associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18: 1722-1726

Stuschke M, Hoederath A, Sack H et al. (1997) Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL.. Cancer 80: 2273–-2284

Suryanarayan K, Shuster J, Donaldson S et al. (1999) Treatment of localized primary non-Hodgkin’s lymphoma of bone in children: A pediatric oncology group study. J Clin Oncol17: 456–459

Swenson WT, Wooldridge JE, Lynch CF et al. (2005) Improved survival of follicular lymphoma patients in the United States. J Clin Onco ;23(22): 5019‒5026

Sweetenham J, Hieke K, Kerrigan M et al. (1999) Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s lymphoma in the U.K. Br J Haematol 106: 47‒54

Talamini R, Montella M, Crovatto M et al. (2004) Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110: 380–385.

Sweetenham JW, Pearce R, Philip T et al. (1994) High-dose chemotherapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin’s lymphoma in patients aged 55 years and over: results from the EMBT. Bone Marrow Transplant 14: 981–987

Swerdlow SH, Campo E, Harris NL et al. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, Genf, Schweiz

Swinnen LJ (1999) Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 26 [Suppl 14]: 21–25

Swinnen LJ (2000) Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 11 [Suppl 1]: 45–48 Tanosaki R, Okamoto S, Akatsuka N et al. (1994) Dose escalation of biweekly cyclophosphamide, doxorubicin,

vincristin, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin’s lymphoma. Cancer 74: 1939–19442004;110(3):380-5

Tavani A, Pregnolato A, Negri E et al. (1997) Diet and risk of lymphoid neoplasms and soft tissue sarcomas. Nutr Cancer 27: 256–260

Taylor AM, Metcalfe JA, Thick J, Mak YF (1996) Leukemia and lymphoma in ataxia telangiectasia. Blood 87: 423–438

Tesch H, Diehl V, Lathan B et al. (1998) Moderate dose escalation for advanced stage Hodgkin’s disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s Lymphoma Study Group. Blood 92: 4560–4567

The International Non-Hodgkin’s Lymphoma Prognostic Factors Project, Shipp MA, Harrington DP, Anderson JR et al. (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–994

Thieblemont C, Berger F, Dumontet C et al. (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95(3): 802–806

Thieblemont C, Felman P, Berger F et al. (2002) Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 3(1):41‒47

Thiede C, Alpen B, Morgner A et al. (1998) Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 16: 3822–3831

Thiede C, Wundisch T, Alpen B et al. (2001) Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 19: 1600–1609

Thiel E, Korfel A, Hinkelbein W (1999) Primary CNS lymphoma: chemotherapy followed by radiotherapy or chemotherapy alone? A randomized multicentric study. Front Radiat Ther Oncol 33: 349–353

Thomson KJ, Morris EC, Bloor A et al. (2009) Favorable long-term survival after reduced – intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 27:426-432

Thorns C, Bastian B, Pinkel D, et al. (2007) Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer 46: 37-44

Tiemann M, Schrader C, Klapper W, et al. (2005) Histopathology, Cell proliferation indices and clinical outcome in 304 patients with Mantle cell lymphoma (MCL): A clinicopathological study from the European MCL network. British Journal of Haematology 131: 29-38

Tilly H, Mounier N, Coiffier B et al. (2001) Superiority of the ACVBP regimen over standard CHOP in the treatment of advanced aggressive NHL. A Study from the GELA. Hematology J 2: 1

Tilly H, Mounier N, Lederlin P et al. (2000) Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87–1 study. Groupe d’Etudes des Lymphomes de l’Adulte. J Clin Oncol 18: 1309–1315

Tirelli U, Errante D, Van Glabbeke M et al. (1998) CHOP is the standard regimen in patients >or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European

Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16: 27–34

Tondini C, Ferreri AJM, Siracusoano L et al. (1999) Diffuse large-cell lymphoma of the testis. J Clin Oncol 17: 2854–2858

Torlakovic E, Cherwitz DL, Jessurun J, Scholes J, McGlennen R. (1997) B-cell gene rearrangement in benign and malignant lymphoid proliferations of mucosa-associated lymphoid tissue and lymph nodes. Hum Pathol 28(2):166‒173

Trappe R, Oertel SH, Choquet S et al. (2005) Sequential treatment with the anti-CD 20 antibody rituximaband CHOP + GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): first results of a multicenter phase II stuy. Blood 106: 932

Troussard X, Valensi F, Duchayne E et al. (1996) Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 93(3): 731‒736

Trümper L, Hartmann F, Kranzhöfer N, Pfreundschuh M (1996) Untersuchungen zur Stadieneinteilung beim M. Hodgkin. Tum Diagn Ther 17: 154–157

Trümper L, Pfreundschuh M (1994) Lymphknotenvergrößerungen. In: Gerok W, Hartmann F, Pfreundschuh M et al. (Hrsg) Klinik der Gegenwart. Urban & Schwarzenberg, München Wien Baltimore

Trümper L, Renner C, Nahler M et al. (1994) Intensification of the CHOEP regimen for high-grade non-Hodgkin’s lymphoma by G-CSF: Feasibility of a 14-day regimen. Onkologie 17: 69–71

Trümper L, Renner Ch, Klöss M, Löffler M, Pfreundschuh M (1998) Dosiseskalation bei hochmalignen Non-Hodgkin-Lymphome. In: Fleischer J, Hiddemann W, Hölzer D (eds) Therapie der Leukämien und Lymphome – Schwerpunkt Zytokine. Karger, Basel Freiburg Paris London, S 231–239

Tsukamoto N, Kojima M, Hasegawa M et al. (2007) The usefulness of 18F-fluorodeoxyglucose positron emission tomography and a comparison with 67 Gallium scintigraphy in the evaluation of lymphoma. Cancer 110: 652‒659

Unterhalt M, Herrmann R, Tiemann M et al. (1996) Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin’s lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 10: 836–843

Uren AG, O’Rourke K, Aravind LA et al. (2000) Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 6: 961–967

van Besien K (2006) The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 20: 235–244

van Besien K, Carreras J, Zhang M (2005) Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma. Blood 106(11)

van Besien K, Ha CS, Murphy S et al. (1998a) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91: 1178–1184

van Besien K, Sobocinski KA, Rowlings PA et al. (1998b) Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92: 1832–1836

van Besien K, Thall P, Korbling M et al. (1997) Allogeneic transplantation for recurrent or refractory non-Hodgkin’s lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 3: 150–156

van Besien KW, Khouri IF, Giralt SA et al. (1995) Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 13: 1096–1102

van Krieken JH, Hoeve MA. Epidemiological and prognostic aspects of gastric MALT-lymphoma. Recent Results Cancer Res 2000; 156: 3–8

van Oers MH, Klasa R, Marcus RE et al. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108: 3295–3301

van Oers MH (2007) Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 92(6): 826‒833

Van Spronsen D, Janssen-Heijnen M, Breed W, Coebergh JW (1999) Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, 1993–1996. Ann Hemat 78: 315–319

Vaughan-Hudson B, Vaughan-Hudson G, MacLennan KA et al. (1994) Clinical stage 1 non-Hodgkin’s lymphoma: long-term followup of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69: 1088–1093

Velasquez WS, McLaughlin P, Fuller LM et al. (1994) Intermediategrade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamidemethotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer 73: 2408–2416

Verdonck LF, van Putten WLJ, Hagenbeek A et al. (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 332: 1045–1051

Visconti J, Petruska P, Dunphy C, Presti M, Dunphy F (2001) Rituximab in the treatment of gastrointestinal mucosa-associated lymphoid tissue lymphoma. Blood 94: 270

Vose J, Link BK, Grossbard ML et al. (1999) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated immediate- or high grade NHL Blood 94: 89a

Vose J, Wahl RL, Saleh M et al. (2000) Multicenter phase II trial of Iodine-131 Tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin`s lymphomas. J Clin Oncol 18: 1316–1323

Warzocha K, Ribeiro P, Bienvenu J et al. (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood 91: 3574–3581

Weide R, Pandorf A, Heymanns J, Koppler H. (2004) Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 45(12): 2445‒2449

Weigert O, Jurczak W, von Schilling C et al. (2006) Efficacy of radioimmunotherapy with (90y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLSG. Annual Meeting of the American Society of Oncology, Atlanta. J Clin Oncol 24 (18S): 7502

Weigert O, Pastore A, Riecken M et al. (2007) Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21 (3): 524-528

Weisenburger DD (1994) Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5 [Suppl 1]: 19–24

Weisenburger DD, Armitage JO (1996) Mantle cell lymphoma – an entity comes of age. Blood 87: 4483–4494 Weisenburger DD, Vose JM, Greiner TC et al. (2000) Mantle cell lymphoma. A clinicopathologic study of 68 cases

from the Nebraska Lymphoma Study Group. Am J Hematol 64: 190–196 Wellmann A, Otsuki T, Vogelbruch M et al. (1995) Analysis of the t (2;5)(p23;q35) translocation by reverse

transcriptionpolymerase chain reaction in CD30+ anaplastic large- cell lymphomas, in other non-Hodgkin’s lymphomas of T-cell phenotype, and in Hodgkin’s disease. Blood 86: 2321–2328

Welzel N, Le T, Marculescu R et al. (2001) Templated nucleotide addition and immunoglobulin JH-gene utilization in t (11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res 61: 1629–1636

Weniger MA, Melzner I, Menz CK et al. (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25: 2679‒2684

Werner CA, Dohner H, Joos S et al. (1997) High-level DNA amplifications are common genetic aberrations in B-cell neoplasms. Am J Pathol 151: 335–342

Wiernik PH, Lossos IS, Tuscano JM, et al. (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26: 4952‒4957

Wigle DT, Semenciw RM, Wilkins K et al. (1990) Mortality study of Canadian male farm operators: non-Hodgkin’s lymphoma mortality and agricultural practices in Saskatchewan. J Natl Cancer Inst 82: 575–582

Willemze R, Kerl H, Sterry W et al. (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90: 354–371

Willenbrock K, Roers A, Blohbaum B, Rajewsky K, Hansmann ML (2000) CD8(+) T cells in Hodgkin’s disease tumor tissue are a polyclonal population with limited clonal expansion but little evidence of selection by antigen. Am J Pathol 157: 171–175

Willich NA, Reinartz G, Horst EJ et al. (2000) Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study. Int J Radiat Oncol Biol Phys 46: 895–901

Willis TG, Jadayel DM, Du MQ et al. (1999) Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96(1): 35‒45

Wiseman GA, White CA, Sparks RB et al. (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 39: 181–194

Wiseman GA, White CA, Witzig TE et al. (1999) Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5: 3281s–3286s

Witzig TE, Flinn IW, Gordon LI et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20(15): 3262‒3269

Witzig TE, Geyer SM, Ghobrial I et al. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-56

Witzig TE, Gordon LI, Cabanillas F et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10): 2453‒2463

Witzig TE, White CA, Wiseman GA et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17: 3793–3803

Wlodarska I, Martin-Garcia N, Achten R et al. (2002) FUSH study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7 as a common abnormality accumulating in forms with features of cytological progression. Genes Chrom Cancer 33: 243-251

Wohrer S, Puspok A, Drach J et al. (2004) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 15(7): 1086‒1090

Wotherspoon AC, Doglioni D, Diss TC et al. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–577

Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG (1991) Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338: 1175–1176

Wündisch T, Neubauer A, Stolte M, Ritter M, Thiede C (2003) B-cell monoclonality is associated with lymphoid follicles in gastritis. Am J Surg Pathol 27(7): 882‒887

Wundisch T, Thiede C, Morgner A et al. (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23(31): 8018‒8024

Yahalom J (1999) Radiation therapy in the treatment of lymphoma. Curr Opin Oncol 11: 370–374 Young RC, Longo DL, Glatstein E et al. (1988) The treatment of indolent lymphomas: watchful waiting v aggressive

combined modality treatment. Semin Hematol 25 [Suppl 2]: 11–16 Zahm SH, Blair A (1992) Pesticides and non-Hodgkin’s lymphoma. Cancer Res 52 [Suppl]: 5485s–5488s Zettl A, Ott G, Makulik A et al. (2002) Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J

Pathol 161: 1635-1645 Zettl A, Rüdiger T, Konrad MA et al. (2004) Genomic profiling of peripheral T-cell lymphoma, unspecified, and

anaplastic large cell lymphoma delineates novel recurrent chromosomal aberrations. Am J Pathol 164: 1837-1848 Zhang Q, Siebert R, Yan M et al. (1999) Inactivating mutations and overexpression of BCL10, a caspase recruitment

domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 22(1): 63‒68 Zhang Y, Holford TR, Leadere B et al. (2004). Blood transfusion and risk of non-Hodgkin’s lymphoma in Conneticut

women. Am J Epidemiol 160: 325-330 Zhang Y, Holford TR, Leaderer B et al. (2004) Prior medical conditions and medication use and risk of non-Hdogkin

lymphoma in Connecticut United States women. Cancer Causes Control 15: 419-428 Zhang Y, Sanjose SD, Bracci et al. (2008): Personal use of hair dye and the risk of certain subtypes of non-Hodgkin-

lymphoma. Am J Epidemiol 167: 1321-1331 Zhou H, Du MQ, Dixit VM. (2005) Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT

lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7(5): 425‒431 Zimber-Strobl U, Strobl L, Hofelmayr H et al. (1999) EBNA2 and c-myc in B cell immortalization by Epstein-Barr virus

and in the pathogenesis of Burkitt’s lymphoma. Curr Top Microbiol Immunol 246: 315–320; discussion 321 Zinzani PL, Bendandi M, Frezza G et al. (1996) Primary mediastinal B-cell lymphoma with sclerosis: clinical and

therapeutic evaluation of 22 patients. Leuk Lymphoma 21: 311–316 Zinzani PL, Martelli M, Bendandi M et al. (2001) Primary mediastinal large B-cell lymphoma with sclerosis: a clinical

study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 86: 187–191 Zinzani PL, Martelli M, Magagnoli M et al. (1998) Anaplastic large cell lymphoma Hodgkin’s-like: a randomized trial of

ABVD versus MACOP-B with and without radiation therapy. Blood 92: 790–794 Zinzani PL, Martelli M, Magagnoli M et al. (1999a) Treatment and clinical management of primary mediastinal large

B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 94: 3289–3293

Zinzani PL, Martelli M, Storti S et al. (1995) Phase III comparative trial using CHOP vs. CIOP in the treatment of advanced-grade non-Hodgkin’s lymphoma. Leukemia Lymphoma 19: 329–335

Zinzani PL, Pavone E, Storti S et al. (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VN-COP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 89: 3974–3979

Zinzani PL, Pulsoni A, Perrotti A et al. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22(13): 2654‒2661

Zinzani PL, Storti S, Zachariah A et al. (1999b) Elderly aggressive-histology non-Hodgkin’s lymphoma: First-line VNCOP-B regimen experience on 350 patients. Blood 94: 33–38

Zucca E, Bertoni F, Roggero E et al. (1998a) Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 338: 804–810

Zucca E, Bertoni F, Roggero E, Cavalli F (2000) The gastric marginal zone B-cell lymphoma of MALT type. Blood 96: 410–419

Zucca E, Bertoni F. (2006) Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? J Natl Cancer Inst 98(19): 1348‒1389

Zucca E, Cavalli F (2000) Extranodal lymphomas. Ann Oncol 11 [Suppl 3]: 219–222 Zucca E, Roggero E, Bertoni F, Cavalli F (1997) Primary extranodal non-Hodgkin’s lymphomas. Part 1:

Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 8: 727–737 Zucca E, Roggero E, Pileri S (1998b) B-cell lymphoma of MALT type: a review with special emphasis on diagnostic

and management problems of low-grade gastric tumours. Br J Haematol 100: 3–14 Zucca E, Roggero E, Pinotti G et al. (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol 6: 257–262 Zucca E, Stein H, Coiffier B (1994) European lymphoma task force: Report of the workshop on mantle cell lymphoma

(MCL). Annals of Oncology 5: 507–511 Zwick C, Birkmann J, Peter N et al. (2008) Equitoxicity of bolus and infusional etoposide: results of a multicenter

randomised trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma Annals Hematol 87(9): 717‒726